Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
In the UK, from early 2024 to early 2025, approximately 1.6 million adults in England, Wales, and Scotland used GLP-1 class drugs for weight loss, including semaglutide drugs like 'Wegovy' and 'Ozempic', or tirzepatide drugs like 'Mounjaro'
Therefore, when using semaglutide, adverse reactions occur earlier with oral administration compared to subcutaneous injection (Merck, 2017)
We discuss how these medications work to promote weight loss, the source of their side effects, and the newer compounds soon to overcome some of those side effects, such as muscle loss
We will talk about your medical history and your weight loss goals
We find it in oral form (ampoules, liquid form), as well as in food supplements in the form of capsules or tablets
PMID 10880854
